- Home
- Publications
- Publication Search
- Publication Details
Title
Role of erbB3 receptors in cancer therapeutic resistance
Authors
Keywords
-
Journal
ACTA BIOCHIMICA ET BIOPHYSICA SINICA
Volume 46, Issue 3, Pages 190-198
Publisher
Oxford University Press (OUP)
Online
2014-01-22
DOI
10.1093/abbs/gmt150
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Oncogenic ERBB3 Mutations in Human Cancers
- (2013) Bijay S. Jaiswal et al. CANCER CELL
- Src Family Kinases as Novel Therapeutic Targets to Treat Breast Cancer Brain Metastases
- (2013) S. Zhang et al. CANCER RESEARCH
- Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3
- (2013) Ethan V. Abel et al. JOURNAL OF CLINICAL INVESTIGATION
- Targeted therapy for HER2 positive breast cancer
- (2013) Jason A Incorvati et al. Journal of Hematology & Oncology
- Computational Modeling of ERBB2-Amplified Breast Cancer Identifies Combined ErbB2/3 Blockade as Superior to the Combination of MEK and AKT Inhibitors
- (2013) D. C. Kirouac et al. Science Signaling
- Relief of Feedback Inhibition of HER3 Transcription by RAF and MEK Inhibitors Attenuates Their Antitumor Effects in BRAF -Mutant Thyroid Carcinomas
- (2013) Cristina Montero-Conde et al. Cancer Discovery
- Efficacy of HER2-targeted therapy in metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors
- (2012) Dorte L. Nielsen et al. BREAST
- Dual Targeting of EGFR and HER3 with MEHD7945A Overcomes Acquired Resistance to EGFR Inhibitors and Radiation
- (2012) S. Huang et al. CANCER RESEARCH
- Current approaches and future directions in the treatment of HER2-positive breast cancer
- (2012) Sara A. Hurvitz et al. CANCER TREATMENT REVIEWS
- Activation of HER Family Signaling as a Mechanism of Acquired Resistance to ALK Inhibitors in EML4-ALK-Positive Non-Small Cell Lung Cancer
- (2012) J. Tanizaki et al. CLINICAL CANCER RESEARCH
- HER3 Overexpression and Survival in Solid Tumors: A Meta-analysis
- (2012) Alberto Ocana et al. JNCI-Journal of the National Cancer Institute
- Inhibition of doxorubicin-induced HER3-PI3K-AKT signalling enhances apoptosis of ovarian cancer cells
- (2012) Martin Bezler et al. Molecular Oncology
- Survivin in Solid Tumors: Rationale for Development of Inhibitors
- (2012) David N. Church et al. Current Oncology Reports
- Resistance to EGFR-Targeted Therapy: A Family Affair
- (2011) Gregory Vlacich et al. CANCER CELL
- Toward the Prognostic Significance and Therapeutic Potential of HER3 Receptor Tyrosine Kinase in Human Colon Cancer
- (2011) A. Beji et al. CLINICAL CANCER RESEARCH
- Targeting survivin in cancer: the cell-signalling perspective
- (2011) Jagat R. Kanwar et al. DRUG DISCOVERY TODAY
- Novel anti-ErbB3 monoclonal antibodies show therapeutic efficacy in xenografted and spontaneous mouse tumors
- (2011) Luigi Aurisicchio et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Chemotherapy-Based Treatment for Castration-Resistant Prostate Cancer
- (2011) Bostjan Seruga et al. JOURNAL OF CLINICAL ONCOLOGY
- Progression of metastatic castrate-resistant prostate cancer: impact of therapeutic intervention in the post-docetaxel space
- (2011) A Oliver Sartor Journal of Hematology & Oncology
- Impacting tumor cell-fate by targeting the inhibitor of apoptosis protein survivin
- (2011) Ronan J Kelly et al. Molecular Cancer
- Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways
- (2011) Siyuan Zhang et al. NATURE MEDICINE
- Phosphoproteomic mass spectrometry profiling links Src family kinases to escape from HER2 tyrosine kinase inhibition
- (2011) B N Rexer et al. ONCOGENE
- Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab
- (2011) K. Yonesaka et al. Science Translational Medicine
- HER-3 Overexpression Is Prognostic of Reduced Breast Cancer Survival
- (2010) Connie G. Chiu et al. ANNALS OF SURGERY
- ErbB3 expression promotes tumorigenesis in pancreatic adenocarcinoma
- (2010) J. Spencer Liles et al. CANCER BIOLOGY & THERAPY
- An Activated ErbB3/NRG1 Autocrine Loop Supports In Vivo Proliferation in Ovarian Cancer Cells
- (2010) Qing Sheng et al. CANCER CELL
- The Rebirth of a Phoenix: Ovarian Cancers Are Addicted to ErbB-3
- (2010) Gordon B. Mills et al. CANCER CELL
- Heterotrimerization of the Growth Factor Receptors erbB2, erbB3, and Insulin-like Growth Factor-I Receptor in Breast Cancer Cells Resistant to Herceptin
- (2010) X. Huang et al. CANCER RESEARCH
- HER3 Comes of Age: New Insights into Its Functions and Role in Signaling, Tumor Biology, and Cancer Therapy
- (2010) M. R. Campbell et al. CLINICAL CANCER RESEARCH
- Mechanisms of resistance to HER family targeting antibodies
- (2010) Tim J. Kruser et al. EXPERIMENTAL CELL RESEARCH
- Elevated expression of erbB3 confers paclitaxel resistance in erbB2-overexpressing breast cancer cells via upregulation of Survivin
- (2010) S Wang et al. ONCOGENE
- H1047R phosphatidylinositol 3-kinase mutant enhances HER2-mediated transformation by heregulin production and activation of HER3
- (2010) A Chakrabarty et al. ONCOGENE
- ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation
- (2010) Fumin Shi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics
- (2010) Dhara N. Amin et al. SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY
- An overview of HER-targeted therapy with lapatinib in breast cancer
- (2009) Heather McArthur ADVANCES IN THERAPY
- ErbB receptors and signaling pathways in cancer
- (2009) Nancy E Hynes et al. CURRENT OPINION IN CELL BIOLOGY
- Estrogenic Promotion of ErbB2 Tyrosine Kinase Activity in Mammary Tumor Cells Requires Activation of ErbB3 Signaling
- (2009) B. Liu et al. MOLECULAR CANCER RESEARCH
- Evaluation of the prognostic and predictive value of HER family mRNA expression in high-risk early breast cancer: A Hellenic Cooperative Oncology Group (HeCOG) study
- (2008) A K Koutras et al. BRITISH JOURNAL OF CANCER
- A Central Role for HER3 in HER2-Amplified Breast Cancer: Implications for Targeted Therapy
- (2008) S. T. Lee-Hoeflich et al. CANCER RESEARCH
- Phosphatidylinositol 3-Kinase Hyperactivation Results in Lapatinib Resistance that Is Reversed by the mTOR/Phosphatidylinositol 3-Kinase Inhibitor NVP-BEZ235
- (2008) P. J.A. Eichhorn et al. CANCER RESEARCH
- HER3 Is a Determinant for Poor Prognosis in Melanoma
- (2008) M. Reschke et al. CLINICAL CANCER RESEARCH
- Acquired Resistance to Small Molecule ErbB2 Tyrosine Kinase Inhibitors
- (2008) F. L. Chen et al. CLINICAL CANCER RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started